<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367315</url>
  </required_header>
  <id_info>
    <org_study_id>CCOX189A2361</org_study_id>
    <nct_id>NCT00367315</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)</brief_title>
  <official_title>A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of
      patients with knee osteoarthritis (OA)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall OA pain intensity in the target knee on a 0-100 mm Visual Analog Scale (VAS) at 13 weeks.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's global assessment of disease activity on a 0-100 mm VAS at 13 weeks.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's functional status using Western Ontario and McMaster Universities Arthritis Index (WOMAC©) total score at 13 weeks.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Overall OA pain intensity in the target knee using 0-100 mm VAS, at weeks 2, 4, 8.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of disease activity using 0-100 mm VAS, at weeks 2, 4, 8.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's functional status using WOMAC© Likert 3.1 sub-scale scores and total score, at weeks 2, 8, 13.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's health status using the Short Form-36 (SF-36), at week 13.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment of disease activity using 0-100 mm VAS, at weeks 2, 4, 8.</measure>
  </secondary_outcome>
  <enrollment>1684</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumiracoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary osteoarthritis of knee (confirmed by American College of Rheumatology [ACR]
             criteria).

          -  Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.

        Exclusion Criteria:

          -  Evidence of active peptic ulceration within 12 months prior to the screening visit or
             history of active gastrointestinal bleeding within the previous 5 years.

          -  Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Nuernberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, lumiracoxib, celecoxib, cyclooxygenase-2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Lumiracoxib</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

